# NCT04408638 (NCT04408638)

> A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04408638
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Diffuse Large B-cell Lymphoma
- Interventions: Obinutuzumab; Glofitamab; Rituxumab; Tocilizumab; Gemcitabine; Oxaliplatin
- Enrollment: 270
- Primary outcome: Overall survival (OS), defined as the time from randomization to date of death from any cause

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses STARGLO as a confirmatory randomized comparison of glofitamab plus GemOx with R-GemOx in relapsed or refractory DLBCL, including its overall-survival endpoint and role for transplant-ineligible patients. Discussion covers the FDA review and whether the trial population and regional findings are applicable to patients in the United States. Speakers raise questions about regional differences, global recruitment, and the relevance of R-GemOx as a control amid changing treatment options, including CAR-T, as well as how the trial should inform treatment practice and access.

## Indexed commentary on NCT04408638 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 76
- YouTube: 73
- Podcasts: 40
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04408638

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04408638", "email": "<work email>"}; the inbox owner confirms by the emailed link.